Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
April 20, 2009
- OHARA to Improve Tablet Distinguishability by ID Printing on Both Sides of Tablet
April 20, 2009
- So-net M3 Survey Shows Physicians Depend on Internet for Information
April 20, 2009
- JPDSC to Construct PGx Database for the Japanese
April 20, 2009
- GENERICS NEWS IN BRIEF
April 20, 2009
- MIN-IREN Protests against MTPC for Data Falsification
April 20, 2009
- Wyeth Files BLA for Prevnar 13 in US
April 20, 2009
- % of Prescriptions Allowing Generic Substitution Down to 52%: Nihon Chouzai
April 20, 2009
- 40 Medical Bills for Zyprexa Rejected due to Problems such as Overdoses
April 20, 2009
- Soaring Medical Expenses Are Mainly due to Drugs: Dr Nakagawa
April 20, 2009
- Some Med Facilities Do Not Apply for KRAS Gene Test as Senshin-Iryo
April 20, 2009
- Additional Economic Stimulation Measures Target Unapproved Drugs
April 20, 2009
- Lifestyle Intervention May Be as Effective as Medication in Japanese with Early Diabetes: DIANA Study
April 20, 2009
- CDFS to Review Japan's First Ca Blocker + ARB Combination
April 20, 2009
- Council on Regulatory Reform Calls For Continued Permission of Online Sale of OTC Drugs
April 20, 2009
- 20% of Hospitals in Shiga Pref. Prohibit Use of Generics as a Rule
April 20, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
- Daiichi Sankyo, Eli Lilly Launch Prasugrel in UK
April 20, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…